Roche

Roche is the 5th largest pharmaceutical company in the world, based on annual sales, which were recorded at $36,017m in 2009. The pharmaceutical products of Roche are major players in the followin...

EPO rDNA Roche

Digoxin Globulin ovine Fab Roche

Interleukin-2 receptor Mab rDNA Roche

Top 50 Biopharma Products 2011

Ronald A. Rader, president of the Biotechnology Information Institute provided Contract Pharma a list of the Top 57 Biopharma Products by 2011 revenues (in millions). Mr. Rader subscribes to the sam...

Partnering with Roche: Think Roche, Think Partnering

Roche is a top pharma company active in partnering, licensing and M&A in pharmaceuticals and biotechology. Roche has an active partnering group that recognizes the significant role played by 3rd p...

Roche: What they look for in a partner

In this episode of PharmaTelevision News Review, Paul Larsmon talks with Dan Zabrowski, Global Head of Pharma Partnering at Roche. Filmed at BIO-Europe 2009, they discuss: • what Roche is currently...

Roche: Partnering and Global Activity

In this episode of PharmaTelevision News Review, Fintan Walton talks with Bardia Akbari, Global Head of Partnering, Inflammation and AutoImmune at Hoffmann-La Roche. Filmed at AusBiotech 2009, they di...

Roche CEO: No new buyout bid for Illumina

Illumina will not receive a new purchase offer from Roche Holding, Roche CEO Severin Schwan told Der Sonntag.  -More- 

Roche Agree To Release All Trial Data On Tamiflu Drug

The BMJ can reveal that following over three years of talks with pharmaceutical giant Roche, the Cochrane Collaboration is at last being granted access to "all 74 Roche-sponsored trials" of the influe...

Roche, Dan Zabrowski talks about changes in the industry as Roche celebrates 10 years of Roche Pharma Partnering

In this episode of PharmaTelevision News Review, filmed at BIO 2011, Fintan Walton talks to Dan Zabrowski, Head of Partnering at Roche.

Open letter to Roche about oseltamivir trial data

Dear JohnI am writing to you in your capacity as a member of the board of Roche. As you may be aware, the BMJ has been working with the Cochrane Collaboration in its efforts to get Roche to release......

Roche: M&A activity 2005-2013

Roche has announced 21 M&A deals since 2005, with the lead deals being the acquisition of Genentech and Ventana Medical Systems. Abstracted from: Partnering Deals and Alliances with Roche Roche se...

Evaluation of the interference of hemoglobin, bilirubin, and lipids on Roche Cobas 6000 assays.

Pre-analytical error accounts for major total laboratory errors. We assessed the impacts of hemolysis, icterus, and lipemia on laboratory tests on Roche Cobas 6000.

4-Substituted-7-N-alkyl-N-acetyl 2-aminobenzothiazole amides: drug-like and non-xanthine based A2B adenosine receptor antagonists.

7-N-Acetamide-4-methoxy-2-aminobenzothiazole 4-fluorobenzamide (compound 1) was chosen as a drug-like and non-xanthine based starting point for the discovery of A(2B) receptor antagonists because of i...

Glycine Transporter (GlyT1) Inhibitors with Reduced Residence Time Increase Prepulse Inhibition without Inducing Hyperlocomotion in DBA/2 Mice.

Inhibition of the glycine transporter type 1 (GlyT1) leading to potentiation of the glycine site (GlyB) on the N-methyl-d-aspartate (NMDA) receptor has been proposed as a novel therapeutic approach fo...

Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): Discovery of EPPTB (RO5212773).

High throughput screening of the Roche compound library identified benzanilides such as 1 and 2 as antagonists of TAAR1. Optimisation of this hit series led to the first selective TAAR1 antagonist (N-...

Prevalence trends in Sweden of the new variant of Chlamydia trachomatis.

ABSTRACT In 2006 a new variant of Chlamydia trachomatis (nvCT) was discovered in Sweden that was not detectable with Abbott m2000 (Abbott) and Amplicor/COBAS Amplicor/TaqMan48 (Roche). The proportion...